Compare Quest Diagnostics Inc (DGX) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs NEOS S&P 500 High Income ETF — how do they compare? Quest Diagnostics Inc trades at $230.9 (market cap $25.48B), while NEOS S&P 500 High Income ETF trades at $53.97 (market cap $12.50B). The key difference: Quest Diagnostics Inc is far larger — about 2× NEOS S&P 500 High Income ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while NEOS S&P 500 High Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and NEOS S&P 500 High Income ETF for 57 Days on average.
| DGX | SPYI | |
|---|---|---|
Market Cap | $25.48B | $12.50B |
Volume | 941,866 | 3,058,962 |
Sector | Health | Income / Options Overlay |
52-Week High | $247.45 | $54.42 |
52-Week Low | $173.49 | $47.98 |
Typical Hold Time | 56 Days | 57 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% on the day, with the stock showing strong fundamental performance including three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.04B in 2025. Technical indicators signal bearish momentum with the current price near key support at $226, while the company maintains solid profitability with 9.19% net income margin and 14.35% ROE. Recent developments include positive clinical study results and a new partnership with Apple Health app for lab testing integration.
The investment outlook remains positive with analyst consensus target of $250 representing 10% upside potential, though Medicare reimbursement cuts pose near-term headwinds. Growth drivers include advanced diagnostics expansion and consumer testing demand, balanced against technical weakness and regulatory uncertainty. The stock offers value with reasonable P/E of 24.1 and consistent dividend payments.
SPYI trades at $54.01, down 0.13% with a bullish technical outlook from moving averages but neutral oscillators. The ETF maintains consistent monthly dividend distributions around $0.53-$0.54, though recent analysis highlights concerns about principal erosion from covered call strategies. Media coverage focuses heavily on retirement income strategies and the trade-offs between high yields and capital preservation.
The outlook remains cautious as SPYI faces scrutiny over whether its high income distributions come at the expense of long-term capital growth. While technical indicators suggest near-term strength, fundamental concerns about the sustainability of covered call returns and sequence risk for retirees present significant headwinds for investors seeking both income and principal protection.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
